Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have...

Descripción completa

Detalles Bibliográficos
Autores principales: Montemorano, Lauren, Lightfoot, Michelle DS, Bixel, Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938196/
https://www.ncbi.nlm.nih.gov/pubmed/31920338
http://dx.doi.org/10.2147/OTT.S195552
_version_ 1783484001346912256
author Montemorano, Lauren
Lightfoot, Michelle DS
Bixel, Kristin
author_facet Montemorano, Lauren
Lightfoot, Michelle DS
Bixel, Kristin
author_sort Montemorano, Lauren
collection PubMed
description PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.
format Online
Article
Text
id pubmed-6938196
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69381962020-01-09 Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date Montemorano, Lauren Lightfoot, Michelle DS Bixel, Kristin Onco Targets Ther Review PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions. Dove 2019-12-27 /pmc/articles/PMC6938196/ /pubmed/31920338 http://dx.doi.org/10.2147/OTT.S195552 Text en © 2019 Montemorano et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Montemorano, Lauren
Lightfoot, Michelle DS
Bixel, Kristin
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
title Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
title_full Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
title_fullStr Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
title_full_unstemmed Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
title_short Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
title_sort role of olaparib as maintenance treatment for ovarian cancer: the evidence to date
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938196/
https://www.ncbi.nlm.nih.gov/pubmed/31920338
http://dx.doi.org/10.2147/OTT.S195552
work_keys_str_mv AT montemoranolauren roleofolaparibasmaintenancetreatmentforovariancancertheevidencetodate
AT lightfootmichelleds roleofolaparibasmaintenancetreatmentforovariancancertheevidencetodate
AT bixelkristin roleofolaparibasmaintenancetreatmentforovariancancertheevidencetodate

Ejemplares similares